Larimar Therapeutics, Inc. (LRMR)
$2.72
+0.04 (+1.49%)
Rating:
Recommendation:
-
| Symbol | LRMR |
|---|---|
| Price | $2.72 |
| Beta | 0.823 |
| Volume Avg. | 0.05M |
| Market Cap | 48.172M |
| Shares () | - |
| 52 Week Range | 2.4-15.258 |
| 1y Target Est | - |
| DCF Unlevered | LRMR DCF -> | |
|---|---|---|
| DCF Levered | LRMR LDCF -> | |
| ROE | -72.75% | Strong Sell |
| ROA | -66.68% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 24.72% | Neutral |
| P/E | - | |
| P/B | 0.87 | Buy |
Latest LRMR news
About
Download (Excel)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.